Tasian et al., 2015 - Google Patents
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Tasian et al., 2015
View HTML- Document ID
- 947995032514468149
- Author
- Tasian S
- Gardner R
- Publication year
- Publication venue
- Therapeutic advances in hematology
External Links
Snippet
Relapsed and chemotherapy-refractory B-cell acute lymphoblastic leukemia (B-ALL) remain significant causes of cancer-associated morbidity and mortality for children and adults. Development of new molecularly targeted treatment strategies for patients with high-risk B …
- 210000001744 T-Lymphocytes 0 title abstract description 187
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tasian et al. | CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL) | |
| Labanieh et al. | CAR immune cells: design principles, resistance and the next generation | |
| Chavez et al. | CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products | |
| Guedan et al. | Emerging cellular therapies for cancer | |
| Xu et al. | Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives | |
| Tasian | Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? | |
| Watanabe et al. | Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology | |
| Souza-Fonseca-Guimaraes et al. | The emergence of natural killer cells as a major target in cancer immunotherapy | |
| Maus et al. | Chimeric antigen receptor T-cell therapy for the community oncologist | |
| Harris et al. | Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors | |
| Buie et al. | Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia | |
| Firor et al. | From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy | |
| Phipps et al. | Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development | |
| Villanueva et al. | New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1 | |
| Forsberg et al. | The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL | |
| Liu et al. | Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release | |
| Giraudo et al. | Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives | |
| Olson et al. | Adoptive cell therapy for nonhematologic solid tumors | |
| Galanina et al. | Emerging role of checkpoint blockade therapy in lymphoma | |
| Frigault et al. | Chimeric antigen receptor-modified T cells strike back | |
| Han et al. | Chimeric antigen receptor modified T-cells for cancer treatment | |
| McLaughlin et al. | Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances | |
| Swan et al. | Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma | |
| Donini et al. | Cellular immunotherapy targeting cancer stem cells: preclinical evidence and clinical perspective | |
| Xu et al. | Priming leukemia with 5-azacytidine enhances CAR T cell therapy |